News

CeMM warmly congratulations Robert Kralovics, Professor at the Medical University of Vienna and former Principal Investigator at CeMM, who was honored with the Hannes Androsch Prize for his pioneering contributions to molecular hematology and the understanding of the genetic basis of myeloproliferative neoplasms. The award, worth EUR 50,000, was be presented at the Austrian Academy of Sciences on 12 November.

Robert Kralovics' research has fundamentally advanced our understanding of myeloproliferative neoplasms (MPNs), a group of blood disorders characterized by the abnormal production of blood cells. During his time at CeMM and subsequently as a professor at the Medical University of Vienna, he made landmark contributions to uncovering the molecular mechanisms underlying these diseases.

Among his most significant scientific achievements are his contributions to the identification of the JAK2-V617F mutation and the discovery of mutations in the CALR gene. These findings have transformed molecular diagnostics and opened new avenues for the development of targeted therapies. The discovery of CALR mutations was patented for diagnostic and therapeutic applications. CeMM exclusively licensed the diagnostic application to QIAGEN, and the technology is now used worldwide.

Kralovics' research exemplifies the successful translation of fundamental scientific discoveries into clinical applications. His work has not only contributed to identifying the genetic causes of previously poorly understood diseases but has also enabled more precise diagnosis and the development of innovative treatment strategies. His current research focuses on genetic predispositions to hematological disorders and novel immunotherapeutic approaches, particularly for patients with CALR-mutated MPNs. He has also played an important role in bringing scientific discoveries closer to patients through the founding of Myelopro Diagnostics and Research GmbH. Notably, an antibody therapy targeting mutant CALR, developed by Kralovics, is already undergoing clinical evaluation in collaboration with Janssen Oncology/Johnson & Johnson.

Throughout his career, Kralovics has received numerous scientific distinctions, including the prestigious Lieben Prize of the Austrian Academy of Sciences in 2010. The Hannes Androsch Prize now recognizes the exceptional breadth and impact of his achievements, spanning fundamental discoveries, molecular diagnostics, and the development of new therapeutic approaches.

The Hannes Androsch Prize is awarded by the Hannes Androsch Foundation at the Austrian Academy of Sciences and is funded entirely through the foundation's earnings. The EUR 50,000 prize is awarded to Kralovics personally and is dedicated to supporting his research. The award ceremony took place on 12 November at the Austrian Academy of Sciences in Vienna. Following a laudatory address by Sylvia Knapp, member of the foundation's Scientific Advisory Board, the prize certificate was presented by Johann Maurer, Chairman of the Foundation's Board, and OeAW President Heinz Faßmann.